Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): Complete Statistical AnalysisIndependent statistical analysis of NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): primary endpoint results, effect estimate with…
- NKTR-214Independent statistical analysis of A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval,…
- NO16968Independent statistical analysis of NO16968 (NCT00069121), a randomized phase 3 trial of capecitabine plus oxaliplatin versus 5-FU/LV in colorectal cancer, including disease-free survival, relapse-free survival, overall survival, statistical methodology, and interpretation.
- NOA-04Independent statistical analysis of NOA-04, a randomized phase 3 study of sequential radiochemotherapy with PCV or temozolomide in anaplastic glioma.
- NOCTIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults: primary endpoint…
- NOLANIndependent statistical analysis of NOLAN: Naproxen or Loratadine and Neulasta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712009).
- NOM-ERAIndependent statistical analysis of Non-Operative Management and Early Response Assessment in Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03904043).
- Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: primary endpoint…
- NOSE-400Independent statistical analysis of A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04447846).
- Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies: primary endpoint results, effect estimate with confidence interval,…
- NOVEMBERIndependent statistical analysis of Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NRG-GY017Independent statistical analysis of NRG-GY017, a randomized phase 1 trial evaluating atezolizumab before and/or with chemoradiotherapy in patients with node-positive cervical cancer.
- NRRIndependent statistical analysis of Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NSABP B-27Independent statistical analysis of NSABP B-27, a randomized phase 3 trial evaluating preoperative or postoperative Taxotere after preoperative AC in women with surgically removable breast cancer.
- NSABP B-28Independent statistical analysis of NSABP B-28, evaluating the association of the 21-gene recurrence score with local recurrence risk and treatment-related outcomes in breast cancer.
- NSABP B-31An independent statistical analysis of NSABP B-31, the randomized phase 3 trial of doxorubicin and cyclophosphamide plus paclitaxel with or without trastuzumab in women with node-positive HER2-overexpressing breast cancer.
- NSABP B-38Independent statistical analysis of NSABP B-38, a randomized phase 3 trial of combination chemotherapy in women who underwent surgery for node-positive breast cancer, including its design, disease-free survival endpoint, statistical methodology, safety…
- NSABP B-39/RTOG 0413Independent statistical analysis of NSABP B-39/RTOG 0413, a randomized trial comparing accelerated partial breast irradiation approaches with whole breast irradiation in women treated surgically for ductal carcinoma in situ or stage I…
- NSABP B-41An independent statistical analysis of NSABP B-41, a randomized phase 3 study of AC followed by paclitaxel plus trastuzumab, lapatinib, or both before surgery in patients with operable HER2-positive invasive breast cancer.
- NSABP R-04Independent statistical analysis of NSABP R-04, a randomized phase 3 trial evaluating radiation therapy with capecitabine or fluorouracil, with or without oxaliplatin, before surgery in patients with resectable rectal cancer.
- NSCLCIndependent statistical analysis of Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NTRKIndependent statistical analysis of A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OASISIndependent statistical analysis of Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04720664).
- OASIS-4Independent statistical analysis of A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy…
- Obatoclax for Systemic Mastocytosis: Complete Statistical AnalysisIndependent statistical analysis of Obatoclax for Systemic Mastocytosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00918931).
- Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- OCT Pilot in Esophagus: Complete Statistical AnalysisIndependent statistical analysis of OCT Pilot in Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03434834).
- OE05Independent statistical analysis of the OE05 phase 3 randomized trial of combination chemotherapy in patients with esophageal cancer, including its design, survival endpoint, planned statistical analysis, and interpretation.
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03570476).
- Olaparib in Adults With Recurrent/Metastatic Ewing’s Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01583543).
- OLAPCOIndependent statistical analysis of OLAParib COmbinations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576444).
- OLEIndependent statistical analysis of Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03295396).
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…